JP6831324B2 - 特定のタンパク質キナーゼ阻害剤 - Google Patents

特定のタンパク質キナーゼ阻害剤 Download PDF

Info

Publication number
JP6831324B2
JP6831324B2 JP2017523862A JP2017523862A JP6831324B2 JP 6831324 B2 JP6831324 B2 JP 6831324B2 JP 2017523862 A JP2017523862 A JP 2017523862A JP 2017523862 A JP2017523862 A JP 2017523862A JP 6831324 B2 JP6831324 B2 JP 6831324B2
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
conr
thiazolo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017523862A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533232A5 (enExample
JP2017533232A (ja
Inventor
ジャオ，シンドン
ディン，ジャン
メン，リンファ
ゲン，メイユ
リ，トンシャン
シュウ，スウェン
チェン，リン
リウ，チーホン
ワン，シャンロン
ヤン，リジュン
ロン，ユエ
タン，ルイ
ユ，チュイリャン
ジャン，リーファ
リウ，イエンシン
リンフー，リ
スン，ジン
ワン，ウェイボー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Fochon Pharmaceuticals Ltd
Original Assignee
Shanghai Institute of Materia Medica of CAS
Fochon Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS, Fochon Pharmaceuticals Ltd filed Critical Shanghai Institute of Materia Medica of CAS
Publication of JP2017533232A publication Critical patent/JP2017533232A/ja
Publication of JP2017533232A5 publication Critical patent/JP2017533232A5/ja
Application granted granted Critical
Publication of JP6831324B2 publication Critical patent/JP6831324B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2017523862A 2014-11-01 2015-11-01 特定のタンパク質キナーゼ阻害剤 Expired - Fee Related JP6831324B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462073993P 2014-11-01 2014-11-01
US62/073,993 2014-11-01
PCT/CN2015/093551 WO2016066142A1 (en) 2014-11-01 2015-11-01 Certain protein kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2017533232A JP2017533232A (ja) 2017-11-09
JP2017533232A5 JP2017533232A5 (enExample) 2018-12-06
JP6831324B2 true JP6831324B2 (ja) 2021-02-17

Family

ID=55856639

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017523862A Expired - Fee Related JP6831324B2 (ja) 2014-11-01 2015-11-01 特定のタンパク質キナーゼ阻害剤

Country Status (9)

Country Link
US (1) US10328060B2 (enExample)
EP (1) EP3224248B1 (enExample)
JP (1) JP6831324B2 (enExample)
CN (1) CN107207441B (enExample)
AU (1) AU2015341186B2 (enExample)
BR (1) BR112017008867A2 (enExample)
CA (1) CA2966252C (enExample)
ES (1) ES2879809T3 (enExample)
WO (1) WO2016066142A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1232227A1 (zh) * 2014-07-04 2018-01-05 Lupin Limited 作为pi3k抑制剂的喹嗪酮衍生物
WO2017103825A1 (en) 2015-12-18 2017-06-22 Lupin Limited Quinolizinone derivatives as pi3k inhibitors
CA3178569A1 (en) * 2020-05-16 2021-11-25 Zuwen ZHOU Compounds as protein kinase inhibitors
WO2022228387A1 (en) * 2021-04-26 2022-11-03 Fochon Biosciences, Ltd. Compounds as parp inhibitors
WO2023078401A1 (en) * 2021-11-05 2023-05-11 Fochon Biosciences, Ltd. Compounds as protein kinase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS545996A (en) * 1977-06-15 1979-01-17 Yamanouchi Pharmaceut Co Ltd Heterocyclic compounds and process for their preparation
AU5991699A (en) * 1998-09-21 2000-04-10 Biochem Pharma Inc. Quinolizinones as integrin inhibitors
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
KR20090087027A (ko) * 2006-11-13 2009-08-14 일라이 릴리 앤드 캄파니 염증 질환 및 암의 치료를 위한 티에노피리미디논
US8557830B2 (en) 2007-06-07 2013-10-15 Amgen Inc. RAF kinase modulators and methods of use
KR101763656B1 (ko) * 2009-06-29 2017-08-01 인사이트 홀딩스 코포레이션 Ｐｉ3ｋ 저해물질로서의 피리미디논
US8916593B2 (en) 2010-05-04 2014-12-23 Pfizer Inc. Alkoxy-substituted 2-aminopyridines as ALK inhibitors
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
DK2812004T3 (en) * 2012-02-10 2018-10-15 Ptc Therapeutics Inc COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY
WO2013149362A1 (en) 2012-04-06 2013-10-10 Glaxosmithkline Llc 1-(dihydronaphthalenyl)pyridones as melanin-concentrating hormone receptor 1 antagonists
HK1232227A1 (zh) * 2014-07-04 2018-01-05 Lupin Limited 作为pi3k抑制剂的喹嗪酮衍生物

Also Published As

Publication number Publication date
US10328060B2 (en) 2019-06-25
BR112017008867A2 (pt) 2017-12-26
ES2879809T3 (es) 2021-11-23
EP3224248A1 (en) 2017-10-04
US20180036293A1 (en) 2018-02-08
EP3224248A4 (en) 2018-08-08
EP3224248B1 (en) 2021-05-05
WO2016066142A1 (en) 2016-05-06
JP2017533232A (ja) 2017-11-09
AU2015341186B2 (en) 2019-11-14
CN107207441B (zh) 2020-11-24
AU2015341186A1 (en) 2017-06-08
CN107207441A (zh) 2017-09-26
CA2966252A1 (en) 2016-05-06
CA2966252C (en) 2023-10-24

Similar Documents

Publication Publication Date Title
JP6570001B2 (ja) Ａｌｋキナーゼ阻害剤
JP6806342B2 (ja) インドールアミンとしての新規５又は８−置換イミダゾ［１，５−ａ］ピリジン類、及び／又はトリプトファン２，３−ジオキシゲナーゼ
US10022374B2 (en) Certain protein kinase inhibitors
RU2671494C2 (ru) Некоторые ингибиторы протеинкиназы
CA2707030A1 (en) Imidazopyridinones
JP6831324B2 (ja) 特定のタンパク質キナーゼ阻害剤
CA3231988A1 (en) Azaindazole macrocycle compound and use thereof
CN108601773B (zh) 作为pi3k/mtor抑制剂的稠合喹啉化合物
JP2023551272A (ja) ジアシルグリセロールキナーゼ阻害剤としての複素環化合物及びその用途
WO2020233676A1 (en) Amide-substituted imidazo compounds as selective inhibitors of indoleamine 2, 3-dioxygenases
WO2018204286A1 (en) An anti-cancer stemness drug
CA3233233A1 (en) Substituted 1h-pyrazolo [4,3-c] quinolines, methods of preparation, and use thereof
US20160145244A1 (en) Certain protein kinase inhibitors
HK1240216B (zh) 蛋白激酶抑制剂
CA3178569A1 (en) Compounds as protein kinase inhibitors
HK1240216A1 (en) Certain protein kinase inhibitors
HK1218119B (en) Certain protein kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181024

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210128

R150 Certificate of patent or registration of utility model

Ref document number: 6831324

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees